JP2007509055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509055A5 JP2007509055A5 JP2006535354A JP2006535354A JP2007509055A5 JP 2007509055 A5 JP2007509055 A5 JP 2007509055A5 JP 2006535354 A JP2006535354 A JP 2006535354A JP 2006535354 A JP2006535354 A JP 2006535354A JP 2007509055 A5 JP2007509055 A5 JP 2007509055A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- immediate release
- group
- pharmaceutical composition
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51156003P | 2003-10-15 | 2003-10-15 | |
| US10/961,871 US20050142192A1 (en) | 2003-10-15 | 2004-10-08 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| PCT/US2004/034113 WO2005037287A1 (en) | 2003-10-15 | 2004-10-14 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509055A JP2007509055A (ja) | 2007-04-12 |
| JP2007509055A5 true JP2007509055A5 (https=) | 2007-12-06 |
Family
ID=34704145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535354A Pending JP2007509055A (ja) | 2003-10-15 | 2004-10-14 | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の経口投与 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050142192A1 (https=) |
| EP (1) | EP1682151A1 (https=) |
| JP (1) | JP2007509055A (https=) |
| KR (1) | KR20070029114A (https=) |
| AU (1) | AU2004281806A1 (https=) |
| BR (1) | BRPI0415432A (https=) |
| CA (1) | CA2541402A1 (https=) |
| CO (1) | CO5690561A2 (https=) |
| MX (1) | MXPA06003982A (https=) |
| PA (1) | PA8614901A1 (https=) |
| PE (1) | PE20050480A1 (https=) |
| TW (1) | TW200528113A (https=) |
| WO (1) | WO2005037287A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1622625A1 (en) * | 2003-04-09 | 2006-02-08 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof |
| CA2521313A1 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| GT200400213A (es) * | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
| US20050244365A1 (en) * | 2004-05-03 | 2005-11-03 | Novaflux Biosciences, Inc. | Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers |
| ES2364495T3 (es) | 2005-02-03 | 2011-09-05 | The General Hospital Corporation | Método para tratar cáncer resistente a gefitinib. |
| JP2009514870A (ja) | 2005-11-04 | 2009-04-09 | ワイス | ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ |
| EP2195031A1 (en) * | 2007-08-27 | 2010-06-16 | Wyeth a Corporation of the State of Delaware | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US8673353B2 (en) | 2008-02-11 | 2014-03-18 | Dainippon Sumitomo Pharma Co., Ltd | Tablet having improved elution properties |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| CN105147713A (zh) | 2008-08-04 | 2015-12-16 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| SG174382A1 (en) | 2009-04-06 | 2011-11-28 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| CN102724962B (zh) | 2009-11-09 | 2017-05-17 | 惠氏有限责任公司 | 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| SMT201800657T1 (it) * | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| EP3436022B1 (en) | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| US5124319A (en) * | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
| US5990307A (en) * | 1997-08-01 | 1999-11-23 | American Home Products Corporation | Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid |
| US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
| US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US20020160043A1 (en) * | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| JP4452970B2 (ja) * | 2002-03-27 | 2010-04-21 | 日本臓器製薬株式会社 | ジクロフェナクナトリウム経口製剤 |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| EP1622625A1 (en) * | 2003-04-09 | 2006-02-08 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof |
-
2004
- 2004-10-08 US US10/961,871 patent/US20050142192A1/en not_active Abandoned
- 2004-10-13 TW TW093131004A patent/TW200528113A/zh unknown
- 2004-10-14 CA CA002541402A patent/CA2541402A1/en not_active Abandoned
- 2004-10-14 WO PCT/US2004/034113 patent/WO2005037287A1/en not_active Ceased
- 2004-10-14 JP JP2006535354A patent/JP2007509055A/ja active Pending
- 2004-10-14 AU AU2004281806A patent/AU2004281806A1/en not_active Abandoned
- 2004-10-14 BR BRPI0415432-0A patent/BRPI0415432A/pt not_active IP Right Cessation
- 2004-10-14 KR KR1020067007283A patent/KR20070029114A/ko not_active Withdrawn
- 2004-10-14 MX MXPA06003982A patent/MXPA06003982A/es unknown
- 2004-10-14 PA PA20048614901A patent/PA8614901A1/es unknown
- 2004-10-14 EP EP04795300A patent/EP1682151A1/en not_active Withdrawn
- 2004-10-15 PE PE2004001002A patent/PE20050480A1/es not_active Application Discontinuation
-
2006
- 2006-04-19 CO CO06037154A patent/CO5690561A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509055A5 (https=) | ||
| CN1188422C (zh) | 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯 | |
| US11013722B2 (en) | Therapeutic agent for dyslipidemia | |
| CA2541402A1 (en) | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives | |
| WO2012071517A2 (en) | Novel crystalline forms | |
| CN1703204A (zh) | 含有碱性赋形剂的稳定的药物组合物 | |
| JP2012526094A5 (https=) | ||
| JP2013532652A5 (https=) | ||
| JP2011529468A5 (https=) | ||
| JP2002537258A5 (https=) | ||
| CN1131669A (zh) | 光学活性苯并硫杂庚英衍生物，其制备方法和用途 | |
| JP2006516643A5 (https=) | ||
| JP2011513471A5 (https=) | ||
| CN109803657B (zh) | 药物组合物 | |
| EP2943474B1 (en) | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors | |
| EP1617842A1 (en) | Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these | |
| CN1330547A (zh) | 药用制剂 | |
| EA014383B1 (ru) | Гидрохлорид аморфного лерканидипина | |
| HUE028159T2 (en) | Acid addition salts of risperidone and pharmaceutical compositions containing them | |
| KR20200083545A (ko) | 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도 | |
| WO2010048592A1 (en) | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof | |
| CN1111407C (zh) | 抗癌组合物 | |
| WO2011141431A1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| WO2010054565A1 (zh) | 水溶性(r)-(-)-比卡鲁胺前药、其制备方法及用途 | |
| WO2020171507A1 (ko) | 모노메틸 푸마레이트 유도체 및 이들의 약학적 조성물 |